-Yuichi Sugiyama Researcher Activity Profile

Research Author Detailed Information 

Yuichi Sugiyama Publication Rate By Year

Yuichi Sugiyama has published 1 paper(s) in 2006, 18 paper(s) in 2007, 9 paper(s) in 2008, for a total of 28 research publications in total.

Yuichi Y Sugiyama Author Information

LAST NAME: sugiyama

FIRST NAME: yuichi

INITIALS: Y

AFFILIATION:

Papers

Yuichi Sugiyama's Publication Record

1. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Year Published: 2006
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan.
2. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. Year Published: 2007
Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
3. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Japan, and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
4. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. Year Published: 2007
JCL Bioassay Corporation, Nishiwaki 677-0032, Japan. n.yamane@jclbio.com
5. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan.
6. Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Year Published: 2007
Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
7. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Year Published: 2007
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
8. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. Year Published: 2007
JCL Bioassay Corporation, Nishiwaki 677-0032, Japan. n.yamane@jclbio.com
9. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Year Published: 2007
Pharmacokinetics Laboratory, Mitsubishi Pharma Corporation, Chiba, Japan.
10. Effect of excipients on breast cancer resistance protein substrate uptake activity. Year Published: 2007
Department of Pharmaceutics, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
11. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
12. Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan. sugiyama@mol.f.u-tokyo.ac.jp.
13. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. Year Published: 2007
JCL Bioassay Corporation, Nishiwaki 677-0032, Japan. n.yamane@jclbio.com
14. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Year Published: 2007
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
15. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
16. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
17. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
18. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Year Published: 2007
Pharmacokinetics Laboratory, Mitsubishi Pharma Corporation, Chiba, Japan.
19. Effect of excipients on breast cancer resistance protein substrate uptake activity. Year Published: 2007
Department of Pharmaceutics, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
20. P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier. Year Published: 2008
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. sugiyama@mol.f.u-tokyo.ac.jp.
21. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. Year Published: 2008
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, USA.
22. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Year Published: 2008
The Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, Japan.
23. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. Year Published: 2008
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, USA.
24. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Year Published: 2008
The Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, Japan.
25. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Year Published: 2008
Department of Pharmacokinetics and Non-Clinical Safety, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Yato, Kawanishi, Hyogo, Japan.
26. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Year Published: 2008
Graduate School of Pharmaceutical Sciences, the University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan.
27. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Year Published: 2008
Laboratory for Pharmacogenetics, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), Tokyo 108-8639, Japan.
28. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Year Published: 2008
Laboratory for Pharmacogenetics, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), Tokyo 108-8639, Japan.